CMTM3 Suppresses Proliferation and Osteogenic Transdifferentiation of C2C12 Myoblasts through p53 Upregulation

Enzhao Shen1,2, Meiyu Piao1, Yuankuan Li1

  • 1College of Pharmacy, Research Institute of Pharmaceutical Sciences, Chonnam National University, Gwangju 61186, Republic of Korea.

Cells
|August 28, 2024
PubMed

Insights

CKLF-like MARVEL transmembrane domain-containing 3 (CMTM3) inhibits osteoblast differentiation by stabilizing p53. CMTM3 downregulation promotes osteogenesis, offering insights into bone formation regulation.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Biochemistry

Background:

  • CKLF-like MARVEL transmembrane domain-containing 3 (CMTM3) is implicated in various physiological processes and disease.
  • Emerging evidence suggests CMTM3's role in bone formation, necessitating mechanistic investigation.

Purpose of the Study:

  • To elucidate the role and mechanism of CMTM3 in osteogenic differentiation of C2C12 myoblasts.

Main Methods:

  • BMP4-induced differentiation of C2C12 myoblasts.
  • Analysis of Cmtm3 expression levels.
  • Overexpression and knockdown of Cmtm3.
  • Western blotting and qRT-PCR for p53 and p21.
  • Co-immunoprecipitation to assess Cmtm3-p53 interaction.
  • Ubiquitination assays.
  • Trp53 knockdown experiments.

Main Results:

  • Cmtm3 expression decreased during BMP4-induced osteogenic differentiation.
  • CMTM3 overexpression inhibited proliferation and osteogenesis, while knockdown promoted it.
  • CMTM3 upregulated p53 and p21 protein and mRNA levels.
  • CMTM3 stabilized p53 by inhibiting its ubiquitination and degradation.
  • Trp53 knockdown abolished CMTM3's inhibitory effects on osteogenesis.

Conclusions:

  • CMTM3 negatively regulates myoblast proliferation and osteogenic differentiation.
  • CMTM3 exerts its function by interacting with and stabilizing p53.
  • These findings highlight CMTM3 as a key regulator in osteogenesis and a potential therapeutic target.

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K